$DVLT

Vivasor, Inc. sold $2.9M of DVLT

Vivasor, Inc. sold 5,071,311 shares of Datavault AI Inc. (DVLT) at $0.57 ($2.88M total) on 2026-05-05.

Original reporting
SEC EDGAR · Vivasor, Inc.
Published Jun 3, 2026, 12:40 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 1:04 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$DVLT
Bearish
medium confidence
Mentioned
$DVLT
Relevance
8/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DVLTBearishMed
01

Why it matters

The disclosure provides a fresh datapoint on insider behavior at a specific price ($0.5673) and share count, which can influence short-term sentiment and positioning.

02

Market read

Traders may reassess DVLT’s near-term sentiment given a sizable 10% owner sale at a disclosed price.

03

What to watch

Form 4 timing may not coincide with the actual decision date; also, insider sales can be routine for large holders and may not reflect near-term operating performance.

Relevance 8/10Novelty 8/10Timing: today’s trading window after SEC Form 4 filing (filed 2026-06-02)

Background

SEC Form 4 insider transaction: Vivasor, Inc. (10% owner) reported an open-market sale of DVLT shares.

Company-level read

Ticker impact

$DVLTBearishMedium confidence
Context

10% owner Vivasor, Inc. sold 5,071,311 DVLT shares in an open-market transaction worth about $2.88M, disclosed via Form 4.

Expected impact

Near-term: modest downside/volatility risk; longer-term impact likely limited without additional fundamental catalysts.

Evidence & confidence

This is a disclosed insider sale (not a buy) with a specific size and price, but the filing notes no 10b5-1 plan, increasing interpretive uncertainty.

Market effects

Limited sector read-through; this is company-specific insider activity rather than a sector catalyst.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification, liquidity needs, or pre-planned personal reasons; absence of a 10b5-1 plan doesn’t automatically imply bearish fundamentals.

Key entities

  • Datavault AI Inc.

    DVLT issuer of the securities involved in the insider transaction.

  • Vivasor, Inc.

    Reporter of the Form 4 insider sale of DVLT shares.

Related articles

$DVLTMed

Datavault AI Hit With Securities Lawsuit

Datavault AI Inc. (NASDAQ: DVLT) faces a new securities class action, according to DJS Law Group, alleging the company misled investors about operations, partnerships, and growth prospects. The proposed class period is Sept. 4, 2024 to Oct. 30, 2025. The claims stem largely from a Wolfpack Research report that preceded a ~19% one-day share drop. Lead plaintiff deadline is Oct. 5, 2026.

$DVLTMed

Pomerantz Law Firm Announces the Filing of a Class Action Against Datavault AI Inc. and Certain Officers - DVLT

Pomerantz LLP said it filed a securities class action against Datavault AI Inc. (NASDAQ: DVLT) and certain officers in the Eastern District of Pennsylvania, covering purchases from Sept. 4, 2024 to Oct. 30, 2025. The suit alleges misleading statements about partnerships, trading activity, and compliance. After a Wolfpack Research report on Oct. 31, 2025, DVLT shares fell 19.44% to $2.03.

$DVLTMed

Datavault AI Expands Data Driven Outcome Healthcare

Datavault AI (NASDAQ:DVLT) said it amended its definitive agreement with DataMeds AI (NASDAQ:MEDS) to expand a PharmacyChain blockchain technology licensing relationship into unencumbered commercial healthcare, healthspan and wellness uses. Datavault AI will receive common shares worth about 19.9% of DataMeds’ stock at closing, replacing preferred shares for tax optimization.

$MEDSMed

DataMEDS AI, Inc.: DataMeds AI Expands License with DataVault AI for Data Driven Outcome Healthcare-focused Blockchain and Data Monetization License

DataMeds AI (NASDAQ:MEDS) said it amended its licensing agreement with Datavault AI (NASDAQ:DVLT) to expand PharmacyChain blockchain-related licensing from pharmaceutical distribution to all unencumbered commercial healthcare, healthspan and wellness uses. The deal is tied to a pending multi-party combination and includes DVLT receiving common shares worth about 19.9% of MEDS at closing.